Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 35: 748-754, 1989;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sheldon, R. S.
Right arrow Articles by Duff, H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sheldon, R. S.
Right arrow Articles by Duff, H. J.

Clinical Chemistry, Vol 35, 748-754, Copyright © 1989 by American Association for Clinical Chemistry

Antiarrhythmic drugs and the cardiac sodium channel: current models

RS Sheldon, RJ Hill and HJ Duff
University of Calgary, Cardiovascular Research Group, Alberta, Canada.

The major electrophysiological effect of Class I antiarrhythmic drugs is blockade of the cardiac sodium channel, thereby reducing the initial depolarization of the action potential and slowing impulse propagation. Despite the widespread use of these drugs our understanding of their mechanism of action is incomplete. Models based on electrophysiological studies predict that a receptor for Class I drugs is associated with the sodium channel, and that occupancy of this receptor causes blockade of the sodium channel. Recent radioligand studies with [3H]batrachotoxinin-A benzoate have identified a binding site for Class I drugs associated with rat cardiac myocyte sodium channels, which may be the predicted receptor. Binding of drugs to this site is saturable, reversible, stereospecific, and occurs at pharmacologically relevant concentrations with similar rank order of potency in vivo and in vitro. Drugs appear to bind preferentially to a closed state of the channel, thereby preventing channel opening and subsequent sodium influx.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Association for Clinical Chemistry.